Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Key company updates and project milestones from PARI's partnered programs with pharmaceutical companies.
News published by Savara Inc. concerning MOLBREEVI for the potential treatment of aPAP, administered via an investigational eFlow® Nebulizer System.
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Customization is key
Dr. Stefan Seemann is appointed President of PARI Pharma GmbH
LAMIRA®, an eFlow® Technology nebulizer, is the only device to deliver Insmed’s ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union